Anzeige
Mehr »
Login
Freitag, 22.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Diese Tech-Aktie könnte Ihr Portfolio revolutionieren – und die nächste große Sicherheitslücke schließen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DXL9 | ISIN: US29014R2022 | Ticker-Symbol: 3970
Berlin
16.05.23
12:22 Uhr
6,400 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ELOXX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ELOXX PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ELOXX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEloxx Pharmaceuticals, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB-
17.10.Eloxx Pharmaceuticals passt Optionspreise für CEO an1
17.10.Eloxx Pharmaceuticals, Inc. - 8-K, Current Report1
14.08.Eloxx Pharmaceuticals, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB5
16.07.Eloxx Pharmaceuticals, Inc. - 8-K, Current Report3
ELOXX PHARMACEUTICALS Aktie jetzt für 0€ handeln
11.07.Eloxx Pharmaceuticals Provides Pipeline and Financing Updates226First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations ...
► Artikel lesen
16.04.Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates216ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02...
► Artikel lesen
20.03.Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival ...360NEW YORK" March 20, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of Latch, Inc. Latch, Inc.'s securities were suspended on August...
► Artikel lesen
13.03.Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases372Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready...
► Artikel lesen
13.03.Almirall, S.A.: Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases476Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1